Glenmark

Sector: Pharma & Healthcare (API / Bulk Drug Plant)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Glenmark operates in the pharma & healthcare segment of the Indian market, with a presence noted in the api / bulk drug plant category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Glenmark is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in api / bulk drug plant includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

May 2026

Glenmark Pharmaceuticals has made significant moves in its product portfolio and pipeline. In March 2026, the company launched GLIPIQ (Semaglutide) in India, entering the competitive GLP-1 market alongside Sun Pharma, Dr. Reddy's Laboratories, and Zydus Lifesciences following the semaglutide patent expiry [3][6][8][10]. In December 2025, Glenmark secured multi-regional rights to Hansoh Pharma's oncology drug in a landmark $1 billion deal, substantially expanding its oncology pipeline [2]. More recently, oncology pipeline developments have drawn investor attention, with shares edging higher on positive news flow [1]. The US market also saw activity with Glenmark's vancomycin launch, though trading has been volatile [4].

Financially, Glenmark delivered solid results with Q3 profit rising 16%, driven by strong performance in its India and US operations [5]. These developments reflect Glenmark's dual focus on strengthening its complex generics and specialty pipeline while maintaining growth momentum in core markets.

Sources (8)

1. Glenmark Pharmaceuticals stock (INE935A01035): shares edge higher as oncology pipeline news lifts se - AD HOC NEWS · AD HOC NEWS · Thu, 21 May 2026
2. Glenmark bags multi-regional rights to Hansoh Pharma's oncology drug for $1 B - BioSpectrum Asia · BioSpectrum Asia · Thu, 18 Dec 2025
3. Glenmark Pharmaceuticals unveils GLIPIQ (Semaglutide) In India - BioSpectrum India · BioSpectrum India · Sat, 21 Mar 2026
4. Glenmark Pharmaceuticals stock (INE935A01035): US vancomycin launch and volatile trading draw attent - AD HOC NEWS · AD HOC NEWS · Thu, 21 May 2026
5. Glenmark Q3 profit rises 16% on strong India, US performance - The Economic Times · The Economic Times · Fri, 30 Jan 2026
6. India’s semaglutide race begins: Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals and Zydus Lifescienc.. - ETPharma.com · ETPharma.com · Sat, 21 Mar 2026
7. Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic Semaglutide - The Hindu · The Hindu · Sat, 21 Mar 2026
8. Sun Pharma, Dr Reddy's, Glenmark, Zydus: Pharma stocks in focus after semaglutide patent expires; what investors need to know - Upstox · Upstox · Mon, 23 Mar 2026

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Glenmark occupies a position in the api / bulk drug plant category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on api / bulk drug plant benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the api / bulk drug plant value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Glenmark is a participant in the Indian api / bulk drug plant category, which forms part of the broader Pharma & Healthcare space. The Indian api / bulk drug plant market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Glenmark specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Glenmark mirrors the broader api / bulk drug plant category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Glenmark as a peer benchmark within the api / bulk drug plant category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Glenmark, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Glenmark?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (api / bulk drug plant) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Glenmark and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Glenmark in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.